Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$0.73
▼ $0.02 (-2.7%)
Market data updated: 09/20 11:55 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/20/2026
Market Cap
$137.16M
Day Range
$0.71 - $0.76
52-Week Range
$0.71 - $3.65
Beta
—
Next Earnings
—
Support
$0.71
Resistance
$1.78
NMRA is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
-53.5% (1Y)
Strengths: 2/26 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Liquidity risk
Current ratio: 5.87
Risk
Biggest negative driver
Death Cross
SMA 50 recently crossed below SMA 200
Technical
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
35
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
54
Quality
50
Value
50
Momentum
0
Risk
40
Sentiment
38
Fundamental
41
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Neumora Therapeutics has centered on its leadership and pipeline updates. The company promoted Joshua Pinto to CEO and appointed a new Chief Medical Officer in August 2026. Financial reports showed improved Q2 2026 earnings per share losses, though still negative. Notably, Neumora announced favorable toxicology results for its oral NLRP3 inhibitor, **NMRA-215**, targeting obesity and cardiometabolic diseases, with plans to file an Investigational New Drug (IND) application in Q4 2026. Analysts also adjusted Neumora’s price target downward in July 2026 amid broader concerns about NLRP3-targeting therapies following a failed Phase 3 trial by Novo Nordisk.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Neumora Therapeutics, Inc.. News trend score: 38. Reason: 6 of the last 18 articles are negative, versus 4 positive.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
59
🎯 Conviction (vs. Emotion)
50
Psychology
71
Fundamentals
41
Technical
0
Valuation
50
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Price (3M)
-52%
Market Narrative
28
Fundamental Reality
50
Narrative Gap
-22
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior for NMRA suggests a strong anchoring effect near support (0.8% above), while loss aversion is also prominent due to the 21.9% drop over three months. The absence of FOMO or euphoria aligns with weak momentum (-17.5% ROC) and subdued volume, reinforcing caution. The narrative gap (-25) hints at a disconnect between investor perceptions and fundamentals, though no clear bias dominates beyond anchoring. The key question is whether traders will hold near support or accelerate selling if the 0.8% buffer erodes.
Updated: 09/08/2026, 09:05 PM
What could change this?
👥 What the crowd believes
"Plans to submit an IND application in Q4 of 2026 for NMRA-215, an oral NLRP3 inhibitor in development for obesity and cardiometabolic disease"
"Favorable NMRA-215 toxicology results with planned clinical advancement in 2026"
"Promotes Joshua Pinto to CEO; Names New Chief Medical Officer"
"RBC cuts price target on Neumora Therapeutics to $5 from $7"
📈 7D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 100/100
🔴 Weakest match
Morgan Housel — 4/100
🗣️ Why do they disagree?
This stock splits the historical methodologies into starkly contrasting camps: the most bullish frameworks—like Charles Mackay’s crowd psychology analysis and Howard Marks’ market cycle assessment—see it as a low-risk, potentially favorable position, scoring near perfection because it lacks signs of mania or overextension. Meanwhile, the more cautious or fundamentalist approaches, such as Gerald M. Loeb’s risk-averse stance or Peter Lynch’s growth-at-a-reasonable-price filter, dismiss it outright, flagging excessive volatility, weak fundamentals, or an unfavorable trend. Even Benjamin Graham’s two variants—one moderate, one strict—split on whether the stock qualifies as a bargain, while the efficient-market camp and Morgan Housel’s patience-based lens outright reject it as too unstable for long-term holding. The divide highlights a tension between cyclical optimism (favoring early-stage or oversold conditions) and deep-value or trend-following skepticism.
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 100
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 100
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 99
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 96
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 76
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 70
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 67
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 63
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 35
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 33
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🔴 25
Weak case — Malkiel/Bogle would say a low-cost index is the simpler bet
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🔴 22
Doesn't clear Lynch's growth-at-a-reasonable-price bar
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 13
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 13
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 4
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 12 bearish · 0 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Medium confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
-228.1%
ROA
-124.0%
ROIC
—
EPS
-$1.45
Cash
$182.53M
Total Debt
$114.53M
Current Ratio
5.87
Debt/Equity
1.10
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
$0.64
Tangible Book Value per Share (Tangible NAV)
$0.64
Sentiment based on basic keywords (not AI) — 4 positive, 8 neutral, 6 negative out of the last 18 articles.
Yahoo · 18.9.2026
Yahoo · 4.9.2026
Simply Wall St. · 4.9.2026
MT Newswires · 14.8.2026
GlobeNewswire · 14.8.2026
Benzinga · 14.8.2026
Benzinga · 31.7.2026
MT Newswires · 27.7.2026
GlobeNewswire · 27.7.2026
Benzinga · 27.7.2026
MT Newswires · 13.7.2026
Simply Wall St. · 11.7.2026
Insider Monkey · 7.7.2026
Insider Monkey · 2.7.2026
MT Newswires · 18.6.2026
Insider Monkey · 17.6.2026
Clinical Trials Arena · 16.6.2026
Zacks · 16.6.2026
Neumora Therapeutics, Inc. (NMRA) currently has a StockIQ AI score of 35/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
NMRA currently scores 35/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
NMRA's technical score is 0/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Current ratio: 5.87; Current ratio: 5.87.
Based on the real signals StockIQ computed: SMA 50 recently crossed below SMA 200; ATR: 14.3% of price; Calmar: -0.63 (3y annualized return -60.7% / max drawdown 96.9%).
StockIQ has no recorded dividend payment history for NMRA.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 5 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Aurora Daljit Singh | Open Market Sale | 21.8.2026 | 21,055 | -21,055 | $1.60 |
| Aurora Daljit Singh | Exercise of Derivative Securities | 21.8.2026 | 21,055 | -21,055 | — |
| Aurora Daljit Singh | Open Market Sale | 21.8.2026 | 20,553 | -20,553 | $1.59 |
| Aurora Daljit Singh | Exercise of Derivative Securities | 21.8.2026 | 20,553 | -20,553 | — |
| Aurora Daljit Singh | Exercise of Derivative Securities | 21.8.2026 | 21,055 | +21,055 | $0.72 |
| Aurora Daljit Singh | Exercise of Derivative Securities | 21.8.2026 | 20,553 | +20,553 | $0.72 |
| BERNS PAUL L | Grant/Award from Employer | 20.8.2026 | 500,000 | +500,000 | — |
| Aurora Daljit Singh | Open Market Sale | 20.8.2026 | 67,741 | -67,741 | $1.51 |
| Aurora Daljit Singh | Grant/Award from Employer | 20.8.2026 | 200,000 | +200,000 | — |
| Milligan Michael Lee | Grant/Award from Employer | 20.8.2026 | 175,000 | +175,000 | — |
| Duncan Jason | Grant/Award from Employer | 20.8.2026 | 375,000 | +375,000 | — |
| Aurora Daljit Singh | Exercise of Derivative Securities | 20.8.2026 | 21,685 | -21,685 | — |
| Aurora Daljit Singh | Exercise of Derivative Securities | 20.8.2026 | 21,685 | +21,685 | $0.72 |
| Aurora Daljit Singh | Exercise of Derivative Securities | 20.8.2026 | 67,741 | -67,741 | — |
| Aurora Daljit Singh | Exercise of Derivative Securities | 20.8.2026 | 67,741 | +67,741 | $0.72 |
| Aurora Daljit Singh | Exercise of Derivative Securities | 20.8.2026 | 45,026 | -45,026 | — |
| Aurora Daljit Singh | Open Market Sale | 20.8.2026 | 66,711 | -66,711 | $1.51 |
| Aurora Daljit Singh | Exercise of Derivative Securities | 20.8.2026 | 45,026 | +45,026 | $0.72 |
| Pinto Joshua | Grant/Award from Employer | 20.8.2026 | 500,000 | +500,000 | — |
| Aurora Daljit Singh | Exercise of Derivative Securities | 19.8.2026 | 17,732 | -17,732 | — |
| Aurora Daljit Singh | Exercise of Derivative Securities | 19.8.2026 | 30,918 | -30,918 | — |
| Aurora Daljit Singh | Exercise of Derivative Securities | 19.8.2026 | 13,268 | -13,268 | — |
| Aurora Daljit Singh | Exercise of Derivative Securities | 19.8.2026 | 13,268 | +13,268 | $0.72 |
| Aurora Daljit Singh | Open Market Sale | 19.8.2026 | 30,918 | -30,918 | $1.65 |
| Aurora Daljit Singh | Exercise of Derivative Securities | 19.8.2026 | 17,732 | +17,732 | $0.72 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
8,027,660 shares short as of 2026-08-31 · vs. 7,622,548 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
53.4% of trading volume this week was short selling, vs. 42.5% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology